Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you have IBS and you're considering Wegovy, the honest answer is that IBS is not a contraindication to semaglutide — but the medicine's gastrointestinal effects mean the combination deserves careful thought before you start. Wegovy works partly by slowing how quickly food leaves your stomach, and that same mechanism can stir up nausea, loose stools or constipation, all of which overlap with symptoms you may already be managing day to day. There is no blanket rule that puts IBS patients outside the licensed criteria; the decision rests with a prescriber who can weigh your specific pattern of symptoms, triggers and any other medicines you take. Wegovy is a prescription-only medicine and every decision about starting it follows a clinical assessment — not a tick-box form.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
That's a reasonable worry. Semaglutide's most common side effects are gastrointestinal: nausea, vomiting, diarrhoea and constipation each appear in a meaningful proportion of people taking it, particularly in the early weeks of treatment. For someone whose gut is already sensitive, those effects land on top of an existing condition rather than a clean baseline.
The pattern matters a great deal. If your IBS runs predominantly toward loose stools and urgency, the diarrhoea that some people experience in the first few weeks of Wegovy could intensify that pattern temporarily. If your IBS is predominantly constipation-type, semaglutide's gastric-slowing action might actually worsen that, or in some individuals provide modest relief, the evidence here is anecdotal rather than from controlled trials. Mixed-type IBS sits somewhere in between, which makes prediction harder still. The detailed look at Wegovy and IBS on this site goes further into what the current evidence suggests for each subtype.
What clinicians generally look for is whether your IBS is currently well-controlled or actively flaring. Starting any new medicine during a bad flare complicates interpretation: if your gut worsens in week two, is it the drug or is it IBS? A prescriber who knows your history can help you plan the timing and set realistic expectations about the first month.
The NHS semaglutide medicines page lists the common side effects in plain language and is worth reading before your consultation.
Wegovy activates GLP-1 receptors in the gut wall as well as the brain. One result is delayed gastric emptying, food moves more slowly from the stomach into the small intestine. For most people this is what produces the fullness and reduced appetite that drives weight loss. For someone with IBS, particularly if visceral sensitivity is part of the picture, a slower-moving gut can mean more bloating, more distension discomfort, or shifts in transit time that destabilise whatever equilibrium you've reached.
Nausea is the most frequently reported side effect overall and tends to peak after each dose increase. People with a sensitive upper GI tract often find it more pronounced. The standard approach of titrating slowly (starting at the lowest dose and moving up only when the previous dose is well tolerated) is exactly the kind of cautious path that can make the difference for someone with IBS. That titration schedule is something your prescriber sets; it is not something to self-manage.
It is also worth knowing that some people with IBS find that significant weight loss itself changes their symptom pattern, sometimes for the better. Visceral fat, diet quality and gut motility are interconnected. None of this is a promise, it is a reason the conversation is more nuanced than a simple yes or no.
If reflux or GERD is part of your gut history alongside IBS, the guidance on Wegovy and GERD covers that overlap separately. Similarly, if you are managing an autoimmune condition such as lupus, the page on whether you can take Wegovy if you have lupus addresses that specific combination and the considerations it raises.
A thorough consultation will cover more than your BMI. For someone with IBS, the relevant questions include: which subtype you have and how well controlled it currently is; what medicines you already take for it (antispasmodics, loperamide, laxatives, antidepressants used for gut pain); whether you have had any investigations to rule out other conditions; and whether any of your current triggers (fatty food, large meals, stress) are likely to interact with the changes Wegovy brings to eating patterns.
Stopping and restarting semaglutide is also a consideration worth raising at the outset. If your IBS flares badly in the first few weeks, knowing in advance what the plan is (whether to pause, slow the titration, or push through) is more useful than deciding in the middle of a bad fortnight. The page on stopping Wegovy explains what the clinical guidance says about pausing and resuming treatment.
On the practical side: if treatment goes ahead, your medication arrives via tracked DPD delivery in plain, unbranded packaging, so there is nothing to work out at the pharmacy counter, and you can start at a time that suits your schedule rather than your gut's worst day.
For broader context on what the treatment involves and how private access works, the weight-loss treatments page sets out what a consultation with our prescribers covers. Cost is a fair question too, the Wegovy cost page explains what a private prescription typically includes and what to watch for in pricing.
Our clinical team reviews every consultation personally. If IBS is part of your medical history, that detail goes to a named prescriber (not an algorithm) and is weighed properly. If you have questions in advance, our support team is available seven days a week.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.